



Industry Interactive Discussion: IID01

Industry session financially supported by Teva Pharmaceuticals during the 38th ECNP Congress

Innovation in Early-Phase Schizophrenia Treatment - Leveraging Long-Acting Injectables for Optimized Care

Sunday 12 October 2025 13:00 – 13:30

Room G104



Andrea Fiorillo, MD, PhD
Professor of Psychiatry
Department of Psychiatry
University of Campania "Luigi Vanvitelli"
Naples, Italy

Join us at this Industry Interactive Discussion as we delve into the role of long-acting injectable antipsychotics in the early treatment of schizophrenia, including:

- The importance of early intervention from a clinical and healthcare system perspective
- How advances in formulation may enhance clinical care: Results from the SOLARIS study
- Opportunities to align the needs and perspectives of healthcare professionals and patients: Insight from the ADVANCE study



This material is intended for HCPs only

NPS-NL-NP-00241
Date of Preparation: August 2025

Teva Pharmaceuticals Europe BV, Busweg 1,
2031 DA Haarlem, Netherlands. KvK 003973190.

